Applied Clinical Trials Online2d
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...
News-Medical.Net3d
Study uncovers how MAGE-4 and Pten loss promote aggressive tumor growth
A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response critical for their elimination.
MAGE-A4 protein promotes tumor progression by suppressing immune responses, mouse study finds
A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response ...
Health Canada approves MSD’s Keytruda for NSCLC stages
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
Hospital Healthcare Europe5d
Lung cancer pathway insights from Dr Zaheer Mangera part 2: neoadjuvant therapy
Dr Zaheer Mangera discusses the evolution of the neoadjuvant lung cancer pathway and notable changes to the TNM standards.